ADAMTS13 or Caplacizumab Reduces the Accumulation of Neutrophil Extracellular Traps and Thrombus in Whole Blood of COVID-19 Patients under Flow.

Significantly increased neutrophil NETosis, reduced NETosis reserve, and enhanced thrombus formation under arterial shear may play a crucial role in pathogenesis of COVID-19 associated coagulopathy. Recombinant ADAMTS13 or caplacizumab may be explored for the treatment of COVID-19 associated thrombosis.